Ebola vaccine 'safe to use' in Africa

The video discusses the ongoing efforts to combat the Ebola outbreak in Africa, highlighting the development of experimental vaccines that have shown safety in trials conducted on healthy Ugandans. The diversity of the African population presents a unique challenge for vaccine makers, as a successful vaccine in Africa could work globally. The trials have passed phase one, showing a positive immune response, but effectiveness against the disease remains uncertain. Ongoing trials, including those in Oxford, are crucial in the fight against Ebola, with significant progress being made.

What significant progress have scientists made in Africa regarding Ebola and Marburg viruses?

• They have created experimental vaccines that are safe.

• They have developed a cure for the viruses.

• They have eradicated the viruses.

• They have stopped the spread of the viruses.

Why is Africa considered a unique challenge for vaccine makers?

• Because of its large population.

• Due to its economic conditions.

• Because of its geographical size.

• Due to the diversity of its people.

What was the outcome of the phase one trials for the vaccine?

• The vaccine showed a positive immune response.

• The vaccine caused severe side effects.

• The vaccine was ineffective.

• The vaccine was not tested.

Where are some of the ongoing trials for the Ebola vaccine taking place?

• In Uganda only.

• In Oxford and Uganda.

• In America only.

• In Asia.

What is the significance of the ongoing trials for the Ebola vaccine?

• They have no significant impact.

• They are expected to eradicate Ebola immediately.

• They are forming the basis for more potent vaccines.

• They are only for academic purposes.